Cell lines and transfections
HEK293, Vero E6 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM, GIBCO) and HeLa cells were grown in Roswell Park Memorial Institute 1640 medium (GIBCO). HepG2 cells were grown in Minimum Essential Medium (MEM, GIBCO) supplemented with a 1% Nonessential Amino Acid Solution (NEAA, GIBCO). All media were supplemented with 10% heat-inactivated fetal bovine serum (GIBCO), 2 mM L-glutamine, 100 units/ml penicillin and 100 units/ml streptomycin, and cells were grown at 37°C under an atmosphere with 5% CO2. Primary human umbilical vein endothelial cells (HUVECs) were grown in EGM-2 medium (Lonza) supplemented with 2% FBS, 0.04% hydrocortisone, 0.4% hEGF-B, 0.1% VEGF, 0.1% R3-IGF-1, 0.1% ascorbic acid, 0.1% hEGF, 0.1% GA-1000 and 0.1% heparin. Cells were treated with forskolin (FSK, Selleck), H89 (Selleck), 666-15 (MCE), KG-501 (Selleck), T-705 (Selleck), and lipopolysaccharide (LPS, Sigma) as noted in the text. Transient transfection was performed with Lipofectamine 3000 (Invitrogen) according to the manufacturer’s instructions.
Mice
C57BL/6N AKIP1 knockout (Akip1-/-) mice were generated by CRISPR-Cas9-mediated gene targeting by Cyagen Biosciences Inc., Suzhou. Briefly, Cas9 and AKIP1 gRNA targeting exon 4 (TGATCTGACTCCATCAGGCGAGG and ATACTACTTGTCTATGCCAGAGG) were coinjected into fertilized eggs. The Akip1-/- genotype was confirmed by PCR followed by sequence analysis using primers (Mouse Akip1-F: 5’- GTTCTCTCCCCAGCTTCTCAGTC -3’; Mouse Akip1-R: 5’- GCACCCATGTAGTTGAAAATAAAGC -3’), and 114 bp in exon 4 was demonstrated to be deleted. WT C57BL/6N mice (except littermates of Akip1-/- C57BL/6N mice) and BALB/c mice were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. All mice were raised in the animal core facility at the Institute of Military Medical Sciences in accordance with the animal welfare requirements. 10 weeks old mice were used in the experiment otherwise indicated.
Vectors and viruses
Flag-tagged VP35, PRKACA (the catalytic subunit of PKA) and VP35 mutants were constructed by cloning the gene fragments into a pcDNA3.0-based Flag-vector (Invitrogen). Myc-tagged AKIP1 and mutants were constructed by inserting the gene fragments into the pCMV-Myc-vector (Clontech). GFP-tagged VP35 was expressed by cloning the genes into pEGFP-C1 (Clontech, Takara Bio). All the constructs were validated by Sanger DNA sequencing.
The small interfering RNA (siRNA) targeting AKIP1 (sense, 5’-GCAGUUGAU UCUGGACAAATT-3’; antisense, 5’-UUUGUCCAGAAUCAACUGCTT-3’) (AKIP1 RNAi) and scrambled siRNA (sense, 5’-UUCUCCGAACGUGUCACGUTT -3’; antisense, 5’-ACGUGACACGUUCGGAGAATT-3’) (si-control) were purchased from Genepharma Technologies (Suzhou, China). All siRNA transfections were performed using Lipofectamine 3000 (Invitrogen).
Recombinant adenoviruses (Type 5 adenoviruses with deletion of E1a and E3a genes) expressing VP35 (Ad-VP35) were obtained from Beijing BAC Biological Technologies. Analogous adenoviruses expressing GFP (Ad-GFP) or null (Ad-null) were used as controls. Live EBOV (Mayinga strain) is preserved by the BSL4 Lab in Wuhan Institute of Virology, Chinese Academy of Sciences.
Immunoprecipitation and immunoblot analysis
Cell lysates were prepared in lysis buffer containing 1% Nonidet P-40 and protease inhibitor cocktail (Roche)42. Soluble proteins were immunoprecipitated using anti-Flag (M2, Sigma), anti-Myc (Sigma), anti-VP35 (Creative Diagnostics), anti-CREB1 (Cell Signaling Technology) antibodies, or anti-mouse IgG antibody as a negative control (Sigma). An aliquot of the total lysate (5%, v/v) was included as a control. Immunoblotting was performed with horseradish peroxidase (HRP)-conjugated anti-Myc (Sigma), HRP-conjugated anti-Flag (Sigma), HRP-conjugated anti-β-actin (Sigma), anti-Phospho-(Ser/Thr) PKA substrate (Cell Signaling Technology), anti-VP35 (Creative Diagnostics), anti-L (Creative Diagnostics), anti-NP (Sino Biological), anti-AKIP1 (Abcam and Thermo), anti-pCREB1-133 (Abcam), anti-CREB1 (Abcam and Cell Signaling Technology), anti-c-Fos (Abcam), anti-phosphoserine (Abcam), anti-thrombomodulin (Abcam), anti-SerpinB2 (Abcam), or anti-PRKACA (BD). The antigen-antibody complexes were visualized via chemiluminescence (ECL system, GE Healthcare). A PageRuler Western marker (Thermo) was used as a molecular weight standard.
Purification of EBOV VP35 protein
EBOV VP35 proteins were expressed as His-tagged fusion proteins in E. coli BL21 (DE3) in Luria broth medium. EBOV VP35 protein expression was induced at an OD600 (optical density at 600 nm) of 0.6 with 0.2 mM isopropyl-D-thiogalactopyranoside (IPTG) and continued for 4 h at 37°C. Cells were then harvested and suspended in buffer (20 mM Tris and 8 M urea, pH 8.0). Suspended cells were sonicated and clarified by centrifugation at 12,000 rpm at 4°C for 15 min. Then, VP35-His protein was purified using a Ni column (Ni NTA beads 6FF), eluted with buffer (20 mM Tris, 8 M urea, and 500 mM imidazole, pH 8.0), and dialyzed to buffer (20 mM Tris-HCl and 300 mM NaCl, pH 8.0) for renaturation. The purity of the samples was determined by SDS-PAGE.
Quantitative RT-PCR
Total cellular RNA or viral RNA was extracted using the RNeasy mini (QIAgen, USA) or viral RNA mini (QIAgen, USA) according to the manufacturer’s protocol respectively. For cDNA synthesis, 0.5 μg of RNA was reverse transcribed using ReverTra Ace qPCR RT master mix with gDNA remover (FSQ-301, Toyobo). The primer sequences are shown in Extended Data Table 1. The samples were denatured at 95°C for 2 min, followed by 40 cycles of amplification (15 s at 94°C for denaturation, 60 s at 60°C for annealing and extension). Quantitative RT-PCR was performed using SYBR Green Real-time PCR Master Mix (QPK-201, Toyobo) with the QuantStudio 6 Flex multicolor real-time PCR detection system (ABI). Relative mRNA levels to GAPDH were calculated using the 2-ΔΔCT method43. Means (upper limit of the box) ±SEM (error bar) of 3 independent experiments were presented in the figures.
In situ proximity ligation assay
The Duolink in situ proximity ligation assay (PLA) (Sigma) was used to detect the endogenous association of AKIP1 and VP35 in cells. In brief, HepG2 cells plated on glass coverslips were transfected with the plasmid expressing GFP-VP35. After fixation with 4% formaldehyde, cells were permeabilized with 0.3% Triton X-100 in PBS for 15 min. After blocking with blocking buffer, the cells were incubated with rabbit anti-AKIP1 (Abcam) or rabbit anti-GFP (Abcam) and mouse anti-VP35 (Creative Diagnostics) primary antibodies. anti-VP35 or anti-AKIP1 alone was employed as a negative control. Nuclei were stained with DAPI (blue). The red fluorescent spots generated from the DNA amplification-based reporter system combined with oligonucleotide-labeled secondary antibodies were detected with a Zeiss LSM 800 Meta confocal microscope (Carl Zeiss). Means (upper limit of the box) of the complexes number and ±SEM (error bar) from 10 cells were presented.
Immunofluorescence microscopy
Cells were transfected, fixed, permeabilized and blocked as described above. Then, after incubation with anti-AKIP1 (or other indicated primary antibodies) overnight at 4°C, the cells were washed three times with blocking solution and then incubated with FITC- or TRITC-conjugated goat anti-rabbit (or anti-mice) IgG. The cells were then stained with DAPI after washing, and imaged using a laser scanning confocal microscope (Zeiss LSM 800 Meta) with a 63× immersion oil lens. The intensity of CREB1 in the cytoplasm and the nucleus were analyzed by Image J.
Gene silencing using siRNA
For gene knockdown in HepG2 cells, cells maintained in 6-well plates were transfected with 100 pmol AKIP1 siRNA (sense, 5’- GCAGUUGAUUCUGGACAAATT -3’; antisense, 5’- UUUGUCCAGAAUCAACUGCTT -3’) or the same concentration of scrambled control siRNA (sense, 5’- UUCUCCGAACGUGUCACGUTT -3’; antisense, 5’- ACGUGACACGU UCGGAGAATT -3’) with Lipofectamine 3000 (Invitrogen) according to the manufacturer’s recommendations. For the minigenome assay, HEK293T cells were transfected with 100 pmol AKIP1 siRNA with Lipofectamine 3000. The minigenome assay was performed 24 h after siRNA transfection.
Generation of the AKIP1 knockout HepG2 cell line using CRISPR-Cas9 system
The AKIP1 knockout cell lines were generated using the pSpCas9(BB)-2A-Puro (PX459) vector (Addgene plasmid no. 48139), with a single guide RNA (sgRNA) targeting the human AKIP1 gene. The sgRNA sequences (target sequence 1: TGGCGGCCGCAGCGCTGAAT; target sequence 2: CATGTCTATCGTTATCA CAG) were designed using a CRISPR design web tool (http://crispr.mit.edu). The DNA sequences encoding sgRNAs were cloned into the CRISPR-Cas9 vector. Cells were transfected with the sgRNA vectors, and stable clones were screened by puromycin (1 μg/ml). Frameshift mutations in AKIP1 gene were confirmed by sequencing and immunoblotting.
Luciferase reporter assay
Cells were seeded in 24-well plates and transfected with indicated amount of Flag-VP35, 200 ng of the CRE reporter plasmid (Promega, USA) and 4 ng of Renilla luciferase plasmid. An empty vector was used to ensure the same plasmid concentration in each well. After stimulation with or without 25 μM FSK for 4 h, the cells were harvested, and the luciferase activity of the cell lysates was analyzed with the dual-luciferase reporter assay system (Promega, USA) and measured in a TD-20/20 luminometer. Values were obtained by normalizing the luciferase values to the Renilla values. Fold induction was determined by setting the vector transfection without Flag-VP35 and without FSK as a value of 1.
PKA kinase activity assay
A PKA kinase activity kit was used (Enzo, USA) for the assay, which is based on a solid phase enzyme linked immunosorbent assay (ELISA) that utilizes a specific peptide as a substrate for PKA and a polyclonal antibody that recognizes the phosphorylated form of the substrate. Briefly, HepG2 cells were infected with Ad-VP35 or Ad-GFP at a MOI of 10. 48 h after infection, the cells were lysed, and the protein concentration was determined using the bicinchoninic acid (BCA) method. The PKA kinase activity in HepG2 cells was assayed according to the manufacturer’s instructions. In brief, samples were added to wells of the PKA substrate microtiter plate. Then, diluted ATP was added to each well to initiate the reaction and incubated at 30°C for 90 min. Next, phosphospecific substrate antibody was added. After incubating at room temperature for 60 min, the diluted anti-rabbit IgG: HRP conjugate was added to each well and incubated at room temperature for 30 min. After washing, TMB substrate was added and incubated at room temperature for 30 min. Finally, stop solution was added, and the absorbance was measured at 450 nm. The relative kinase activity in cell lysate = (Average absorbance of sample-Average absorbance of blank) /Quantity of crude protein used per assay.
EBOV minigenome assay
The replication of EBOV in the cells was evaluated by the minigenome system24. Briefly, producer cells (p0) were co-transfected with p4cis-vRNA-RLuc (250 ng), pCAGGS-T7 (250 ng) expressing T7 RNA polymerase, and 4 plasmids expressing EBOV proteins (pCAGGS-NP (125 ng), pCAGGS-VP35 (125 ng), pCAGGS-VP30 (75 ng), and pCAGGS-L (1,000 ng)). One day after transfection, the medium was replaced with medium containing 5% FBS, and then incubated for another 3 days. Target cells (p1 or later) were transfected with pCAGGS-NP (125 ng), pCAGGS-VP35 (125 ng), pCAGGS-VP30 (75 ng), pCAGGS-L (1,000 ng) and pCAGGS-Tim (250 ng), incubated for 24 h, and then infected with replication and transcription-competent virus-like particles (trVLPs) from the p0 (or P1) supernatant for 24 h, and then cultured for another 3 days in medium containing 5% FBS. Virus replication was either determined by the intra-cellular luciferase activities using the Renilla-Glo luciferase assay kit (Promega, E2710) after cell lysis by passive lysis buffer (PLB; Promega), or by viral RNA level determined by reverse-transcription and quantitative real-time PCR.
Sucrose density gradient centrifugation
Sucrose gradient centrifugation was employed to fraction cell lysates as previously described15. WT and AKIP1-/- HepG2 cells grown in 100-mm dishes were transfected with plasmids expressing pCAGGS-NP (1.25 μg), pCAGGS-VP35 (1.25 μg), pCAGGS-VP30 (0.75 μg), pCAGGS-L (10 μg), pCAGGS-T7 (2.5 μg) and p4cis-vRNA-RLuc (2.5 μg). After 48 h, the cells were harvested and homogenized in 1 ml of lysis buffer (10 mM HEPES (pH 7.5), 12.5% sucrose, 1 mM EDTA, and 1× protease/phosphatase inhibitor cocktail) for 15 min at 4°C. The samples were then sequentially centrifuged at 700 and 1,000 × g for 5 min. Subsequently, the supernatants were layered onto continuous 25 to 60% sucrose gradients containing 10 mM HEPES (pH 7.5) and 1 mM MgCl2 and then centrifuged at 137,000 × g for 2.5 h using an Optima MAX-XP (Beckman). Fractions were collected from top to bottom in 14-drop (300 μl) fractions. Then, the proteins in each fraction were subjected to immunoprecipitation and immunoblot analysis.
RNA immunoprecipitation (RNA-IP) assays
WT and AKIP1-depleted HepG2 cells were transfected with the plasmids pCAGGS-NP (1.25 μg), pCAGGS-VP35 (1.25 μg), pCAGGS-VP30 (0.75 μg), pCAGGS-L (10 μg), pCAGGS-T7 (2.5 μg) and p4cis-vRNA-RLuc (2.5 μg). After 48 h, the cells were lysed and assayed with the ChIP-IT High Sensitivity kit (53040, Active Motif, USA) as previously described. The CREB1 antibody (#9197, Cell Signaling Technology) was used to precipitate potential bound viral RNA. Precipitated RNA was reverse transcribed and quantified using real-time PCR. Primer pairs from EBOV 3’ leader (3Le, 1-469) and 5’ trailer (5Tr, 18283-18959) as described previously were employed15. The PCR primers are shown in Extended Data Table 1.
EBOV infection assay
WT or AKIP1-depleted HepG2 cells grown in 12-well plates were incubated with EBOV Mayinga strain, at a MOI of 1 for viral proliferation assay or a MOI of 10 for microscopy and qRT-PCR, at 37°C for 1 h. Then, fresh medium was added in the presence/absence of 10 μM H89 or 1 μM 666-15 and incubated at 37°C for 96 h. Subsequently, cells were fixed with 4% formaldehyde for immunofluorescence microscopy, or were lysed in 1 ml TRIzol reagent (Invitrogen) and viral RNA was extracted using a QIAamp viral RNA mini kit (QIAgen, USA) according to the manufacturer’s protocol. EBOV RNA was quantitatively analyzed by reverse transcription and qRT-PCR. The viral titers were determined by plaque formation assay. Briefly, 10-fold serial diluted samples were added into a 96-well plate containing 1×104 Vero E6 cells per well. Cells were observed for cytopathic effect and the titers were expressed as median tissue culture infective dose (TCID50). All work with live EBOV was performed in BSL4 containment.
mRNA expression microarray analysis
SurePrint G3 human gene expression 8x60k v2 microarray from Agilent was used for trancriptome analysis. Briefly, HepG2 cells were transfected with the plasmids Flag-VP35 or Flag. 48 h later, total RNA was extracted using the RNeasy mini kit (QIAgen, USA) according to the manufacturer’s protocol. After first-strand cDNA synthesis with Poly-dT primer and second-strand cDNA synthesis, the cDNA was subjected to Gene Expression Microarray analysis following the manufacturer’s protocol. The chips were scanned with a GeneChip Scanner G2565CA (Agilent) and analyzed with Agilent Feature Extraction (v10.7) and GeneSpring software V13 (Agilent).
Tail bleeding time
Bleeding time was measured as previously described44. WT and Akip1-/- C57BL/6N mice (10 weeks, female) were infected with Ad-VP35 or Ad-null (2×109 PFU) via tail vein injection twice at 24 h intervals. Three days after the 2nd injection, WT mice were administered intraperitoneally with/without 2 mg/kg 666-15 (dissolved in 10% DMSO, 40% PEG300, 5% Tween-80 and 45% saline) three times at 24 h intervals. Six days later, the mice were challenged with LPS (5 mg/kg) or saline via their tail vein. After 4 h, the tails of the mice were cut transversely from the tip at 1 cm with surgical scissors. The bleeding tail stump was immediately placed in normal saline at 37°C, and the time was measured until the bleeding stopped.
Coagulation analysis
Mouse coagulation was measured as previously described with modifications39. WT and Akip1-/- mice were infected with Ad-VP35 or Ad-null (3×109 PFU) via tail vein injection twice at 24 h intervals. Six days later, the mice were injected with LPS (5 mg/kg) or saline via their tail vein. After 4 h, blood clotting times and serum FIB concentrations were determined using an automated blood coagulation analyzer (Rayto, RAC-030) according to the manufacturer’s instructions.
Statistical analyses
Graphical representation and statistical analyses were performed using Prism 8 software (GraphPad Software). Unless otherwise stated, results are shown as mean (upper limit of the box) ±SEM (error bar) from 3 or more independent experiments in duplicate. Unpaired two-tailed t-test was used for the analysis of two groups. Survival curves were analyzed by Log-rank test. Data were considered significant when p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***).
Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
Data availability
All data are available from the corresponding author upon reasonable request. Source data are provided with this paper.
Methods references
42 Cao, C., Leng, Y. & Kufe, D. Catalase activity is regulated by c-Abl and Arg in the oxidative stress response. J. Biol. Chem. 278, 29667-29675 (2003).
43 Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-408 (2001).
44 Yang, P. et al. Antithrombotic Effects of Nur77 and Nor1 Are Mediated Through Upregulating Thrombomodulin Expression in Endothelial Cells. Arterioscler. Thromb. Vasc. Biol. 36, 361-369 (2016).